Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) EBITDA: 2019-2024

Historic EBITDA for Centessa Pharmaceuticals (CNTA) over the last 6 years, with Dec 2024 value amounting to -$233.0 million.

  • Centessa Pharmaceuticals' EBITDA fell 28.09% to -$53.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.2 million, marking a year-over-year decrease of 51.42%. This contributed to the annual value of -$233.0 million for FY2024, which is 57.36% down from last year.
  • According to the latest figures from FY2024, Centessa Pharmaceuticals' EBITDA is -$233.0 million, which was down 57.36% from -$148.1 million recorded in FY2023.
  • Centessa Pharmaceuticals' 5-year EBITDA high stood at -$10.9 million for FY2020, and its period low was -$380.3 million during FY2021.
  • Moreover, its 3-year median value for EBITDA was -$218.4 million (2022), whereas its average is -$199.8 million.
  • In the last 5 years, Centessa Pharmaceuticals' EBITDA slumped by 3,387.97% in 2021 and then spiked by 42.57% in 2022.
  • Yearly analysis of 5 years shows Centessa Pharmaceuticals' EBITDA stood at -$10.9 million in 2020, then slumped by 3,387.97% to -$380.3 million in 2021, then surged by 42.57% to -$218.4 million in 2022, then skyrocketed by 32.19% to -$148.1 million in 2023, then slumped by 57.36% to -$233.0 million in 2024.